TCPA Suit on Hold Pending FCC Petitions -
A federal court judge has stayed a class action pending a decision by the Federal Communications Commission on the issue of whether the agency overstepped its bounds by issuing...more
Endo Pharmaceuticals, Inc. and Grüenthal GmbH v. Teva Pharmaceuticals USA, Inc. and Barr Laboratories, Inc.
Case Number: 1:12-cv-08060-TPG-GWG -
Teva delayed more than one year between answering a complaint...more
Endo Pharmaceuticals, Inc. v. Roxane Laboratories, Inc.
Case Number: 1:13-cv-03288-TPG -
Defendant Roxane Laboratories, Inc. (“Roxane”) was sued by Endo Pharmaceuticals, Inc. (“Endo”) when Endo learned that...more
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
AstraZeneca Pharmaceuticals LP et al. v. Pharmadax USA, Inc. et al. 1:14-cv-07105; filed November 3, 2014 in the...more
Endo Pharmaceuticals, Inc. v. Actavis, Inc., et al.
Case Number: 1:12-cv-08985-TPG (Dkt.55) -
Endo brought suit against Actavis, as well as over a dozen other pharmaceutical manufacturers, for allegedly...more
Endo Pharmaceuticals Inc. et al. v. Teva Pharmaceuticals USA, Inc. et al. Inter Partes Review.
Case Number: 1:12-cv-08060-GWG (Dkt. 68) -
One of twelve defendants in patent suits brought by Endo petitioned the...more
Pharmaceutical Facility Inspection Leads to Manufacturer Warning -
After a recent inspection of a pharmaceutical manufacturing facility belonging to Endo International PLC, the U.S. Food and Drug Administration (FDA)...more
Case Name: Endo Pharms. Inc. v. Actavis, Inc., Nos. 2013-1658, -1662, 2014 U.S. App. LEXIS 5879 (Fed. Cir. Mar. 31, 2014) (Circuit Judges Newman, Dyk, and Moore presiding; Opinion by Moore, J.; Dissent-in-part by Dyk) (appeal...more
Endo Pharmaceuticals Inc. v. Actavis, Inc. -
Addressing the issue of implied license, the U.S. Court of Appeals for the Federal Circuit vacated and remanded a lower court’s denial of a preliminary injunction, finding...more
Case Number: 1:12-cv-09261-TPG (Dkt. 76) -
The court denied plaintiffs’ motion to bar Par’s expert Professor Midian from receiving any of their confidential information unless he agreed to a patent prosecution bar. ...more
Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up to create your digest using LinkedIn*
Back to Top